Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK615237PMID: 40460228
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of lisocabtagene maraleucel during breastfeeding nor on breastfeeding after CAR-T cell therapy with lisocabtagene maraleucel. However, some information on other agents indicates that breastfeeding might be acceptable after CAR-T cell therapy. If breastfeeding is attempted following lisocabtagene maraleucel CAR T-cell therapy, infants should be monitored carefully, particularly with B- and T-cell counts and immunoglobulin (IgA, IgG and IgM) blood levels.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Lisocabtagene Maraleucel
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.[Lancet Oncol. 2022]Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, et al. Lancet Oncol. 2022 Aug; 23(8):1066-1077. Epub 2022 Jul 12.
- Review Tisagenlecleucel.[Drugs and Lactation Database (...]Review Tisagenlecleucel.. Drugs and Lactation Database (LactMed®). 2006
- Review Brexucabtagene Autoleucel.[Drugs and Lactation Database (...]Review Brexucabtagene Autoleucel.. Drugs and Lactation Database (LactMed®). 2006
- Review Lisocabtagene Maraleucel for the treatment of B-cell lymphoma.[Expert Opin Biol Ther. 2021]Review Lisocabtagene Maraleucel for the treatment of B-cell lymphoma.Iragavarapu C, Hildebrandt G. Expert Opin Biol Ther. 2021 Sep; 21(9):1151-1156. Epub 2021 Jun 28.
- Review Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.[Future Oncol. 2023]Review Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.St-Pierre F, Gordon LI. Future Oncol. 2023 Jan; 19(1):19-28. Epub 2023 Jan 18.
- Lisocabtagene Maraleucel - Drugs and Lactation Database (LactMed®)Lisocabtagene Maraleucel - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...